Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent to participate in this trial in accordance with local regulations;~2. Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype);~3. Be aged at least 18 years old;~4. Have FEV1 \> 40 % and \< 90% predicted (using NHanes III \[1\]);~5. Be able to perform all the techniques necessary to measure lung function;~6. Be adherent with maintenance therapies (antibiotics and or rhDNase), if used, for at least 80% of the time in the two weeks prior to visit 1 and~7. If rhDNase and/or maintenance antibiotic are being used treatment must have been established at least 1 month prior to screening (Visit 0). The subject should remain on the rhDNase and / or maintenance antibiotics for the duration of the trial. The subject should not commence treatment with rhDNase or maintenance antibiotics during the trial~Exclusion Criteria:~1. Be investigators, site personnel directly affiliated with this trial, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted;~2. Be considered terminally ill or eligible for lung transplantation;~3. Have had a lung transplant;~4. Be using maintenance nebulized hypertonic saline in the 2 weeks prior to visit 1;~5. Have had a significant episode of hemoptysis (\> 60 mL) in the three months prior to Visit 0;~6. Have had a myocardial infarction in the three months prior to Visit 0;~7. Have had a cerebral vascular accident in the three months prior to Visit 0;~8. Have had major ocular surgery in the three months prior to Visit 0;~9. Have had major abdominal, chest or brain surgery in the three months prior to Visit 0;~10. Have a known cerebral, aortic or abdominal aneurysm;~11. Be breast feeding or pregnant, or plan to become pregnant while in the trial;~12. Be using an unreliable form of contraception (female subjects at risk of pregnancy only);~13. Be participating in another investigative drug trial, parallel to, or within 4 weeks of screening (Visit 0);~14. Have a known allergy to mannitol;~15. Be using non-selective oral beta blockers;~16. Have uncontrolled hypertension -i.e. systolic BP \> 190 and / or diastolic BP \> 100;~17. Have a condition or be in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the subject's participation in the trial;or~18. Have a failed or incomplete MTT at trial entry (as evaluated in Section 8.1.1.1).~19. The subject must not commence treatment with rhDNase or maintenance antibiotics during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm A (Type: EXPERIMENTAL): Active treatment. Inhaled Mannitol
- Arm B - Control (Type: PLACEBO_COMPARATOR): Arm B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete